Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome-Reference-Cited by-同舟云学术

Proteomics reveal cap-dependent translation inhibitors remodel the translation machinery and translatome

Published:2021-10 Issue:2 Volume:37 Page:109806
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Ho J.J. David,Cunningham Tyler A.,Manara Paola,Coughlin Caroline A.,Arumov Artavazd^ORCID,Roberts Evan R.,Osteen Ashanti,Kumar Preet^ORCID,Bilbao Daniel,Krieger Jonathan R.,Lee Stephen,Schatz Jonathan H.

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference105 articles.

1. Silvestrol exhibits significant in vivo and in vitro antileukemic activities and inhibits FLT3 and miR-155 expressions in acute myeloid leukemia;Alachkar;J. Hematol. Oncol.,2013

2. Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol;Alinari;Clin. Cancer Res.,2012

3. A translational program that suppresses metabolism to shield the genome;Balukoff;Nat. Commun.,2020

4. Targeting the translation machinery in cancer;Bhat;Nat. Rev. Drug Discov.,2015

5. The biological and therapeutic relevance of mRNA translation in cancer;Blagden;Nat. Rev. Clin. Oncol.,2011

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DMDA-PatA mediates RNA sequence-selective translation repression by anchoring eIF4A and DDX3 to GNG motifs;Nature Communications;2024-09-02

2. Silvestrol, a potent anticancer agent with unfavourable pharmacokinetics: Current knowledge on its pharmacological properties and future directions for the development of novel drugs;Biomedicine & Pharmacotherapy;2024-08

3. Proteomic Discovery of RNA-Protein Molecular Clamps Using a Thermal Shift Assay with ATP and RNA (TSAR);2024-04-19

4. Protein translation: biological processes and therapeutic strategies for human diseases;Signal Transduction and Targeted Therapy;2024-02-23

5. Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer;Journal of Clinical Investigation;2023-12-15